Background: During the COVID-19 pandemic, ambulatory clinic visits were replaced by the implementation of telehealth modalities in most inflammatory bowel disease (IBD) units. Aims: The aim of this study was to assess the efficacy, efficiency, patient satisfaction, and acceptability of using telephone consultation in an IBD unit. Methods: A prospective cohort study was performed in IBD patients who underwent telephone consultation during COVID-19 lockdown (between 16th March and 13th April 2020). To assess the efficacy of this telephone consultation (lockdown visit), nonscheduled visits, emergency consultation, hospital admission, and surgery from lockdown visit to the next scheduled consultation (post-lockdown) were checked. To evaluate efficiency, the time between lockdown visit and post-lockdown consultation was compared with previous consultation (pre-lockdown), and the total number of visits 12 months before and after lockdown visit was checked. A telephone survey was designed to rate perception for a telephone consultation. Results: Out of a total of 274 patients, 220 patients (52.2% male; mean age 49 ± 16 years; Crohn’s disease, n = 126; ulcerative colitis, n = 83; indeterminate colitis, n = 11) were included. Only one patient was consulted at the emergency department, 11 patients needed to rearrange the visit, and none patient underwent surgery before the scheduled post-lockdown visit. The interval to post-lockdown visit compared to pre-lockdown visit increased in 37.7% of patients. The satisfaction survey (n = 185) revealed that 94.6% perceived it was effective. However, 44.4% of patients rather prefer on-site consultation for follow-up. Conclusions: Telemedicine during the COVID-19 pandemic was shown to be effective and efficient to care for IBD patients. In addition, telephone consultation is well accepted by patients in non-extended follow-up periods.

Keywords:
Efficacy, Efficiency, Acceptability, Satisfaction, Telemedicine, Inflammatory bowel disease, COVID-19 pandemic
1.
Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–33.
2.
Bedford J, Enria D, Giesecke J, Heymann DL, Ihekweazu C, Kobinger G, et al. COVID-19: towards controlling of a pandemic. Lancet. 2020;395(10229):1015–8.
3.
Fiorino G, Lytras T, Younge L, Fidalgo C, Coenen S, Chaparro M, et al. Quality of care standards in inflammatory bowel diseases: a European Crohn’s and Colitis Organisation (ECCO) position paper. J Crohns Colitis. 2020;14(8):1037–48.
4.
Danese S, Cecconi M, Spinelli A. Management of IBD during the COVID-19 outbreak: resetting clinical priorities. Nat Rev Gastroenterol Hepatol. 2020;17(5):253–5.
5.
Rubin DT, Abreu MT, Rai V, Siegel CA, International Organization for the Study of Inflammatory Bowel Disease. Management of patients with crohn’s disease and ulcerative colitis during the coronavirus disease-2019 pandemic: results of an international meeting. Gastroenterology. 2020;159(1):6–13.e6.
6.
Rubin DT, Feuerstein JD, Wang AY, Cohen RD. AGA clinical practice update on management of inflammatory bowel disease during the COVID-19 pandemic: expert commentary. Gastroenterology. 2020;159(1):350–7.
7.
El Ouali S, Rubin DT, Cohen BL, Regueiro MD, Rieder F. Optimal inflammatory bowel disease management during the global coronavirus disease 2019 pandemic. Curr Opin Gastroenterol. 2021;37(4):313–9.
8.
Taxonera C, Alba C, Olivares D, Martin M, Ventero A, Cañas M. Innovation in IBD care during the COVID-19 pandemic: results of a cross-sectional survey on patient-reported experience measures. Inflamm Bowel Dis. 2021;27(6):864–9.
9.
Allocca M, Fiorino G, Furfaro F, Gilardi D, Radice S, D’Amico F, et al. Maintaining the quality standards of care for inflammatory bowel disease patients during the COVID-19 pandemic. Clin Gastroenterol Hepatol. 2020;18(8):1882–3.
10.
Lees CW, Regueiro M, Mahadevan U; International Organization for the Study of Inflammatory Bowel Disease. Innovation in inflammatory bowel disease care during the COVID-19 pandemic: results of a global telemedicine survey by the international organization for the study of inflammatory bowel disease. Gastroenterology. 2020;159(3):805–8.e1.
11.
Zhang YF, Qiu Y, He JS, Tan JY, Li XZ, Zhu LR, et al. Impact of COVID-19 outbreak on the care of patients with inflammatory bowel disease: a comparison before and after the outbreak in South China. J Gastroenterol Hepatol. 2021;36(3):700–9.
12.
Arrigo S, Alvisi P, Banzato C, Bramuzzo M, Celano R, Civitelli F, et al. Impact of COVID-19 pandemic on the management of paediatric inflammatory bowel disease: an Italian multicentre study on behalf of the SIGENP IBD Group. Dig Liver Dis. 2021;53(3):283–8.
13.
Britton E, Richardson P, Mian I, Conley T, Byrne D, Boyd H, et al. Letter: covid-19-re-initiating clinical services for chronic gastrointestinal diseases. How and when? Aliment Pharmacol Ther. 2020;52(8):1414–5.
14.
Grunert PC, Reuken PA, Stallhofer J, Teich N, Stallmach A. Inflammatory bowel disease in the COVID-19 pandemic - the patients’ perspective. J Crohns Colitis. 2020;14(12):1702–8.
15.
de Jong MJ, van der Meulen-de Jong AE, Romberg-Camps MJ, Becx MC, Maljaars JP, Cilissen M, et al. Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. Lancet. 2017;390(10098):959–68.
16.
Del Hoyo J, Nos P, Faubel R, Muñoz D, Domínguez D, Bastida G, et al. A web-based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: pilot randomized controlled trial. J Med Internet Res. 2018;20(11):e11602.
17.
Li SX, Thompson KD, Peterson T, Huneven S, Carmichael J, Glazer FJ, et al. Delivering high value inflammatory bowel disease care through telemedicine visits. Inflamm Bowel Dis. 2017;23(10):1678–81.
18.
Aguas Peris M, Del Hoyo J, Bebia P, Faubel R, Barrios A, Bastida G, et al. Telemedicine in inflammatory bowel disease: opportunities and approaches. Inflamm Bowel Dis. 2015;21(2):392–9.
19.
Pang L, Liu H, Liu Z, Tan J, Zhou LY, Qiu Y, et al. Role of telemedicine in inflammatory bowel disease: systematic review and meta-analysis of randomized controlled trials. J Med Internet Res. 2022;24(3):e28978.
20.
Hyde AM, Watt M, Carbonneau M, Eboreime EA, Abraldes JG, Tandon P. Understanding preferences toward virtual care: a pre-COVID mixed methods study exploring the perspectives of patients with chronic liver disease. Telemed J E Health. 2022;28(3):407–14.
21.
Donelan K, Barreto EA, Sossong S, Michael C, Estrada JJ, Cohen AB, et al. Patient and clinician experiences with telehealth for patient follow-up care. Am J Manag Care. 2019;25(1):40–4.
22.
Lahat A, Shatz Z. Telemedicine in clinical gastroenterology practice: what do patients prefer? Therap Adv Gastroenterol. 2021;14:1756284821989178.
23.
Mejía Pérez LK, Sharma N. Incorporating telemedicine in gastroenterology practice and training. Gastroenterology. 2021;160(6):2203.
24.
Solitano V, Alfarone L, D’Amico F, Peyrin-Biroulet L, Danese S. IBD goes home: from telemedicine to self-administered advanced therapies. Expert Opin Biol Ther. 2022;22(1):17–29.
© 2023 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2023
You do not currently have access to this content.